Share rights issue 2017

Not for release, publication or distribution, directly or indirectly, in or into the United States,  Australia, Hong Kong, Japan, Canada, Switzerland, Singapore, South Africa or New Zealand or any other jurisdiction where such action would be prohibited under Swedish law.

CombiGene: announces its intention to offer shareholders the opportunity to subscribe for preference shares. An extraordinary meeting of shareholders in CombiGene AB (publ) (“CombiGene” or “the Company”) voted on 26 January 2017 to carry out a new share issue with preferential rights for the Company’s shareholders for a total amount of approximately MSEK 14.2 (“the Offer”). Shareholders who, as of record day 2 February 2017, hold shares in CombiGene receive (1) subscription right per share. Five (5) subscription rights entitle the holder to subscription for two (2) new shares at a subscription price of SEK 3.00 per share. The subscription period is from 6 February 2017 through 20 February 2017. Via the Offer, the Company’s share capital may increase by at most SEK 472,063,70 to SEK 1, 652,223. The total number of shares may increase by at most 4,720,637 shares to 16,552,230 shares. Under the Offer, a public offer for subscription for shares without subscription rights will also be made. The Company has received subscription commitments and guarantee undertakings corresponding to 80.5 percent of the rights issue.

Relaterade dokument

Pressmeddelande 20170131 >>

Informationsmemorandum >>

Teaser >>

Teckningssedel utan företrädesrätt >>

 

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook